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IN this study we have investigated total fiver RNA
and the expression of mRNA in the rat fiver in
vivo after a slow stimulation of interleukin-1. A
total dose of 4g interleukin-l was administered
via a subcutaneously implanted osmotic mini-
pump over a period of 7 days. Plasma concentra-
tions of 2-macroglobulin manifested a rapid
increase, reaching a peak on day 2, while m-inhi-
bitor-3 manifested a marked initial decrease to
50% of the baseline level, followed by a tendency
to increase again. For measurement of total RNA
and specific mRNAs from the fiver, rats were
sacrificed at different times during the experi-
mental period. Total RNA peaked at 6 h, the level
being approximately 60% higher than baseline
value. Specific mRNA from the liver for 2-macro-
globulin and l-inhibitor-3 were quantified using
laser densitometry on slot blots. The amounts
measured during the experimental period agreed
with the pattern of corresponding plasma
protein levels. From barely detectable amounts at
baseline, 2-macroglobulin mRNA peaked on day
1, and then declined. Levels of m-inhibitor-3
mRNA manifested an initial increase at 3 h, but
then declined and remained low until day 5 when
there was a tendency towards an increase. It was
concluded that the levels of plasma concentra-
tions of 2-macroglobulin and zm-inhibitor-3 are
mainly regulated at the protein synthesis level,
and that long-term interleukin-l release could
not override the initial acute phase protein coun-
teracting mechanism triggered.
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Introduction
Different tissue injuries, such as those due to
trauma, radiation, infection and neoplasia, cause
an inflammatory reaction involving the complex
co-ordination of a variety of cells and inflamma-
tory mediators. One of these mediators, the cyto-
kine interleukin-1 (IL-1), is crucially involved in
this complex series of events. IL-1 is produced
by many different cells, but predominantly by
monocytes and macrophages. It has the cap-
ability of inducing an acute phase protein
response which differs from species to species.
2
In the rat, czi-macroglobulin ((ziM), synonymous
with cz2-acute phase protein, is a positive acute
phase protein, while Czl-inhibitor-3 ((XlI3) is a
negative acute phase protein.
4 They are both
proteinase inhibitors belonging to the thiol ester
protein family. Their amino acid sequences have
been determined.5’ When rats are subjected to
an experimentally induced inflammatory reaction,
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or when IL-1 is administered in vivo, the plasma
concentration of cz2M increases but that of (ZlI3
decreases.3’4’7 The expression of mRNA for both
proteins has earlier been investigated in experi-
mental inflammatory reactions, cz2M having been
shown to be characterized by a marked increase
in mRNA expression
5 but czI by a decrease.’ In a recent study we showed that the initial
changes in the plasma concentrations of xiM and
czI could not be preserved by a slow con-
tinuous stimulation of IL-1.9
The aim of the present study was to compare
total liver RNA and the expression of (z2M and
czI mRNA in the liver after slow continuous IL-1
stimulation in vivo with the corresponding
plasma levels.
Materials and Methods
Animal experiment.. Female Wistar rats (M611e-
gaard Avelslaboratorium A/S, Skensved,
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Denmark) weighing 210-250 g were used. After
the animals had been anaesthetized with an intra-
peritoneal injection of Mebumal(R), their backs
were shaved and disinfected. Through a small
incision in the skin of approximately 15 mm, an
osmotic mini pump (2001, Alzet(R)) was implan-
ted subcutaneously and the wound was closed
with Michel(R) clips. The flowrate of the pump
was 1 lal/h. After implantation of the pumps, the
rots were allowed to wake up. Two rats that
received pumps without IL-1 served as controls,
and 24 animals received pumps containing 4 lag
human recombinant IL-113 (Synergen Inc., USA).
The protein was diluted to appropriate con-
centration in sterile phosphate buffered saline,
pH 7.4 (Dulbecco), with 0.2% (w/v) bovine
serum albumin (Sigma), before being used to fill
the pumps. Blood samples (0.4 ml) was col-
lected from the tails into EDTA containing tubes
and plasma was immediately prepared and
frozen at-70C until analysed. Samples were
taken at 0 h, 3 h, 6 h, 24 h, 3 days, 5 days and 7
days after implantation of the pumps. Two
animals were killed with an overdose of
mebumal(R) after 3 and 6 h, respectively, and four
animals were killed after 24 h, 2, 5 and 7 days,
respectively. Liver biopsies were taken under
sterile conditions and frozen at-70C until ana-
lysed. Liver biopsies from two normal unstimu-
lated rats provided baseline reference levels at
time 0.
During the whole experimental period the rats
had free access to water and standard pellets.
The animal experiments were sanctioned by the
local ethics committee for animal experiments.
Assays.. Rat t2M and 1I
were measured by elec-
troimmunoassay (EIA).
0 Antisera against t2M
and 5113 were prepared as described pre-
viously.’4 In order to measure IL-1 in the rat
plasma a specific biotinylated polyclonal antibody
against human recombinant IL-113 was used in an
enzyme-linked immunosorbent assay. The sensi-
tivity of the assay was 0.15 lag/1.
RNA analysis: RNA from the liver biopsies was
prepared with the guanidine HCl method
11 and
stored as an ethanol precipitate at-70C prior to
use. Four single-stranded 30-34-mer oligonucleo-
tides for rats 2M and aI, respectively, were
produced by British Biotechnology Products Ltd
(Oxon, UK). The probes were modified at the 5’
end by the addition of alkaline phosphatase.
They were used in the form of a cocktail of an
equimolar mixture of the probes for each
protein. The slot blot procedure was performed
as described previously.
12 Five l.tg of mRNA was
analysed. A [3-actin probe was used as internal
standard. Electrophoresis of RNA was performed
on 1% agarose gels containing 6% formaldehyde
while RNA transfer and filter hybridization was
performed as described by Bond and Farmer.1
The probes labelled with alkaline phosphatase
were detected with Lumigen TM PPD, according
to the manufacturer’s instructions (Boehringer
Mannheim GmbH Biotechnica, Mannheim,
Germany).
Laser densitometry: Relative quantification of slot
blots was obtained from appropriately exposed
photographic films using a LKB Ultroscan XL
laser densitometer (Uppsala, Sweden).
Results
No rats manifested any discomfort at any time
during the experiments.
Tissue reactions: Macroscopic cystic formation
with fluid was present around the pumps in rats
from day 2 and throughout the remainder of the
experimental period.
Plasma IL-I levels: In controls and in all plasma
samples at 0 h, 3 h and 6 h, IL-1 concentrations
fell below the sensitivity for the assay used while
in rats with IL-1 containing mini-pumps, plasma
concentrations ranged between 0.15 and 0.44 lag/
in samples from 24 h to 7 days.
Acute phase proteins: Plasma t2M and tlI3 con-
centrations were measured by EIA (Fig. 1). In IL-
l stimulated rats plasma t2M concentrations
were undetectable at time 0, but then increased
reaching a peak at 2 days, after which they
declined during the remainder of the experi-
mental period. From their peak level at time 0,
plasma concentrations of aI gradually
decreased to a nadir at day 3, after which they
increased slightly. In the controls, a slight
increase was seen in tiM levels with a peak at 24
h and there was a minor decrease in aI levels
which persisted throughout the experimental
period.
Total RNet. At 6 h total RNA increased reaching a
level approximately 60% greater than the initial
value (Fig. 2). From days 1 to 7 levels were
approximately 20-25% greater than the initial
value.
mRNA detection: Slot blots were hybridised with
probes for t2M and tlI3 mRNA, and were then
analysed with laser densitometry. t2M mRNA was
barely detectable at time 0 but manifested a clear
increase at 3 h, after which it continued to
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FIG. 1. Plasma levels of (z2M (a) and 0113 (b) measured by EIA, for IL-l-stimulated animals (t) and controls (O). Osmotic mini-pumps
containing IL-1 (4 ILtg) were implanted subcutaneously at time 0 and IL-1 was released slowly over a period of 7 days. Controls (n 2)
received mini-pumps containing vehicle only. To obtain liver biopsies for RNA analysis rats were sacrificed successively, and thus the
number of observations decreases over time (n 26 at O, n 24 at 3 h, n 22 at 6 h, n 20 at day, n 16 at 2 days, n 12 at
3 days, n 8 at 5 days and n 4 at 7 days). Values are given as means -I- standard error of the mean.
increase reaching a peak at 24 h (Fig. 3), before
declining toward the starting level, aI mRNA
manifested an initial increase at time 3 h, but
then decreased reaching a nadir at days 1-3,
after which it tended to increase again (Fig. 3).
Discussion
A variety of different cells and inflammatory
mediators interact in a complex way to overcome
Time (days)
FIG. 2. Total RNA determined with the guanidine HCI method.
Rats were stimulated with a slow IL-1 release from an osmotic
mini-pump subcutaneously implanted. To obtain liver biopsies
rats were sacrificed subsequently (n 2 at O, n 2 at 3 h, n
2at6h, n=4at day, n= 4 at 2 days, n= 4 at 3 days, n=4
at 5 days and n 4 at 7 days). Values are given as means ___
standard error of the mean.
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and heal a tissue injury. IL-1 is one of the most
potent cell activators in this complex series of
interactions. It has the capacity to mediate a
variety of responses such as fever, slow wave
sleep, acute phase response and anorexia. The
two forms of IL-1, 0t and , both act on the IL-1
receptor of which there are also two different
types, called IL-1 receptors I and II.4 Finally,
there is also a true receptor antagonist called IL-1
receptor antagonist.
15 This triad consisting of IL-
l, the IL-1 receptors and the IL-1 receptor
antagonist (IL-lra) is crucially involved in the
inflammatory reaction. An illustration of this is
the fact that a lethal endotoxin shock in rabbits
may be remedied by the administration of
human recombinant IL-lra.
In this work we have studied the effects of a
slow continuous IL-1 stimulation upon total liver
RNA, liver mRNA and plasma concentrations of
(z2M and I in the rat. Four mg IL-1 was ad-
ministered over a period of 7 days. The mini-
pumps were found to deliver IL-1 continuously.
Detectable concentrations (0.15-0.44 btg/1) of IL-
l could be demonstrated in plasma from IL-1 sti-
mulated rats during the period of 24 h to 7 days
while no detectable concentrations of IL-1 could
be demonstrated in samples from 0 to 6 h.
Rat (z2M and aI are both protease inhibitors,
and they are also acute phase proteins.v The
human and the rat protein manifest an amino
acid sequence homology of 73%.
5 Although 2M
is not an acute phase reactant in humans, in the
rat it is both a fast and strong positive acute
phase reactant. Its function in humans is con-
sidered to be solely that of a proteinase inhibitor.a2M and azI 3 mRNA expression after slow IL-I stimulation
E
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FIG. 3. mRNA for (z2M (a) and 0113 (b) measured in continuously IL-l-stimulated rats. Hybridized slot blots were analysed by laser
densitometry for relative quantification by measuring the area. Values are given as means standard error of the mean. To obtain
liver biopsies rats were sacrificed successively (n 2 at O, n 2 at 3 h, n 2 at 6 h, n 4 at day, n 4 at 2 days, n 4 at 3 days,
n= 4 at 5 days and n=4at7 days).
On the other hand, rat 0{113 has no counterpart in
man. In the rat it is one of the most abundant
plasma proteins with a normal concentration of
6-10 g/1. The protein is a proteinase inhibitor,
but also manifests binding capacity for other
18 proteins such as rat 0q-microglobulin which
suggests it to have other complementary
functions. 0{113 clones are capable of binding to
polyclonal specific antisera, as was shown when
a rat liver gt11 cDNA library was screened for
other proteins.8’9
We have induced an acute phase protein
response by a slow continuous stimulation of IL-
l delivered by an osmotic mini-pump implanted
subcutaneously. Plasma 02M concentrations, as
measured by EIA, manifested a rapid increase
starting at 3 h and reaching a maximum at 2
days. A striking feature was the rapid decrease of
this plasma concentration once the peak had
been reached. The results of laser densitometry
of 0{2M mRNA on slot blots from rat livers mani-
fested a similar pattern, though the peak occur-
red on day 1 instead. The longer time taken for
the plasma concentrations to peak is consistent
with the extra time required for protein synth-
esis. The occurrence of the 0{2M mRNA peak on
day 1 (24 h) is consistent with findings in a pre-
vious study by Gehring and co-workers,5 where
the level of 02M mRNA reached a peak 20 h after
induction of an experimental inflammatory reac-
tion in the rat. Hepatic acute phase genes have
been divided into two classes according to the
cytokines that are their main inducers.
2 Class 1
genes are regulated by both IL-1 and IL-6, while
class 2 genes are regulated by IL-6 type genes. As
the rat 0{2M gene belongs to class 2 it is not
induced by IL-1. The 0{2M acute phase response
observed after IL-1 stimulation in this study was
thus probably induced by IL-6 released by IL-1.
Plasma 01I3 concentrations manifested an early
decrease after the start of the IL-1 stimulation,
the nadir occurring at day 3. The levels of
mRNA first manifested an early increase at 3 h,
and were then decreased sevenfold at days 1-5,
but at day 7 again manifested a tendency to
increase. The initial increase is in agreement with
findings in a study by Aiello and co-workers
who noted a 25% increase in 0qI mRNA 6 h
after induction of an experimental inflammatory
reaction in the rat.
When IL-1 is administered in vivo in a slow
release manner, it is not possible to maintain the
increased 02M plasma levels. Therefore some
counteracting mechanism must be triggered by
the initial IL-1 stimulation. Different mechanisms
might be suggested. IL-1 has the capacity of
inducing IL-6 production,
21 which in turn has
been shown to induce IL-lra production in
vivo.
22 In addition, monocytes have also been
shown to produce IL-lra when stimulated by dif-
ferent acute phase proteins like C-reactive
protein and 0q-antitwpsin.2 Another possible
mechanism is the up-regulation of the IL-1 type II
receptor in polymorphonuclear leukocytes, medi-
ated by IL-13, which may act as a ’decoy’ recep-
2425 r It tor for IL-1. Howeve, remains unknown
whether IL-1 can induce production of IL-13 in
vivo.
Total RNA in the liver manifested a marked
increase noted at 6 h after the start of the IL-1
stimulation, after which it decreased to a level
approximately 20-25% greater than the initial
level. The increase of total liver RNA is in agree-
ment with the increase seen after turpentine-
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induced inflammation in the rat.26 The persis-
tence of increased levels of total liver RNA may
be interpreted as a consequence of a slower
course due to the huge numbers of proteins
being produced by the liver, rather than a con-
sequence of a long-term stimulation by IL-1.
To sum up, we have found slow continuous
exposure to IL-1 to induce an acute phase
protein response in (z2M and 5113, characterized
by changes in plasma concentrations and corre-
sponding changes in liver mRNA levels. Although
the IL-1 stimulation continued for 7 days, it was
not possible to maintain the acute phase
response, which suggests the presence of a
counteracting mechanism triggered initially.
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